Zacks: Analysts Expect Kintara Therapeutics, Inc. (NASDAQ:KTRA) Will Post Earnings of -$0.12 Per Share

Equities research analysts expect Kintara Therapeutics, Inc. (NASDAQ:KTRA) to announce earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kintara Therapeutics’ earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.08). Kintara Therapeutics reported earnings of ($0.25) per share during the same quarter last year, which indicates a positive year over year growth rate of 52%. The business is scheduled to issue its next earnings report on Monday, September 20th.

According to Zacks, analysts expect that Kintara Therapeutics will report full-year earnings of ($1.62) per share for the current fiscal year, with EPS estimates ranging from ($1.72) to ($1.51). For the next year, analysts expect that the company will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.73) to ($0.39). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Kintara Therapeutics.

Kintara Therapeutics (NASDAQ:KTRA) last issued its quarterly earnings data on Friday, May 14th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.05).

Separately, Maxim Group reaffirmed a “buy” rating and set a $6.00 price objective on shares of Kintara Therapeutics in a research note on Friday, July 2nd.

Kintara Therapeutics stock traded down $0.01 during mid-day trading on Friday, hitting $1.64. 22 shares of the company’s stock were exchanged, compared to its average volume of 1,678,324. Kintara Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $3.35. The company has a 50 day moving average price of $1.77.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. acquired a new stake in shares of Kintara Therapeutics in the 1st quarter valued at about $27,000. Virtu Financial LLC grew its holdings in shares of Kintara Therapeutics by 144.6% in the 1st quarter. Virtu Financial LLC now owns 41,812 shares of the company’s stock valued at $73,000 after acquiring an additional 24,719 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Kintara Therapeutics by 99.8% in the 1st quarter. Northern Trust Corp now owns 44,142 shares of the company’s stock valued at $77,000 after acquiring an additional 22,050 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Kintara Therapeutics in the 1st quarter valued at about $134,000. Finally, Geode Capital Management LLC bought a new position in shares of Kintara Therapeutics in the 1st quarter valued at about $264,000. 6.83% of the stock is currently owned by hedge funds and other institutional investors.

Kintara Therapeutics Company Profile

Kintara Therapeutics, Inc is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Featured Story: Non-Fungible Token (NFT) Explained

Get a free copy of the Zacks research report on Kintara Therapeutics (KTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.